Trial Profile
A Phase 1b Trial of LY2606368 in Combination With Chemotherapy or Targeted Agents in Advanced and/or Metastatic Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Sep 2021
Price :
$35
*
At a glance
- Drugs Prexasertib (Primary) ; Samotolisib (Primary) ; Cetuximab; Cisplatin; Filgrastim; Fluorouracil; Folinic acid; Granulocyte colony-stimulating factors; Pegfilgrastim; Pemetrexed
- Indications Adenocarcinoma; Adrenocortical carcinoma; Advanced breast cancer; Anal cancer; Biliary cancer; Cancer; Carcinoma; Cervical cancer; Cholangiocarcinoma; Colon cancer; Colorectal cancer; Endometrial cancer; Head and neck cancer; Male breast cancer; Mesothelioma; Neuroendocrine tumours; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Proof of concept
- Acronyms Study JTJF
- Sponsors Eli Lilly and Company (India) Pvt. Ltd
- 24 Sep 2021 According to Results published in the Targeted Oncology, Hematologic toxicity was dose-limiting, therefore, similar to the approach taken in Part A, the protocol was amended to include Cohorts B2 and B3.
- 24 Sep 2021 The study was amended to include Cohorts A2 and A3 to evaluate different approaches (G-CSF and an alternate schedule of prexasertib to maximize the dose intensity of prexasertib in the combination), according to Results published in the Targeted Oncology
- 24 Sep 2021 Results published in the Targeted Oncology